Samsung Bioepis Bevacizumab Nod Sets Stage For EU Throwdown

Aybintio Joins Amgen And Pfizer Avastin Rivals Ready For Expiry

 
• By David Wallace
  
Generate a summary of this article
Listen to this article
Beta

Samsung Bioepis has received a pan-European endorsement from the CHMP for its Aybintio bevacizumab biosimilar. The nod follows two previous European Avastin biosimilar approvals, with market formation believed to be imminent.

EU boxing gloves
Multiple bevacizumab biosimilars could launch upon market formation • Source: Shutterstock

Samsung Bioepis has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending granting a pan-European marketing authorization for its SB8 bevacizumab biosimilar rival to Avastin, under the name Aybintio. Formal European Commission approval typically follows positive CHMP opinions within 67 days.

The nod sets the stage for multiple bevacizumab biosimilars to launch across Europe. While European intellectual property protection for Avastin...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.